J Biol Chem, Vol. 274, Issue 40, 28674-28681, October 1, 1999
Rat B2 Sequences Are Induced in the Hippocampal CA1
Region After Transient Global Cerebral Ischemia*
Xiaodong
Liu
,
James A.
Clemens,
Tinggui
Yin,
Diane T.
Stephenson,
Edward M.
Johnstone,
Yansheng
Du,
Jill A.
Panetta,
Steven
M.
Paul, and
Sheila P.
Little§
From the Neuroscience Research Division, Eli Lilly and Company,
Indianapolis, Indiana 46285
 |
ABSTRACT |
Global brain ischemia causes cell death in the
CA1 region of the hippocampus 3-5 days after reperfusion. The
biological pathway leading to such delayed neuronal damage has not been
established. By using differential display analysis, we examined
expression levels of poly(A) RNAs isolated from hippocampal extracts
prepared from rats exposed to global ischemia and found an up-regulated transcript, clone 17a. Northern blot analysis of clone 17a showed an
approximately 35-fold increase in the ischemic brain at 24 h after
four-vessel occlusion. Rapid amplification of cDNA ends of clone
17a revealed a family of genes (160-540 base pairs) that had the
characteristics of rodent B2 sequences. In
situ hybridization demonstrated that the elevated expression of
this gene was localized predominantly in the CA1 pyramidal neurons. The
level of expression in the CA1 region decreased dramatically between 24 and 72 h after ischemia. The elevated expression of clone 17a was
not observed in four-vessel occlusion rats treated with the compound
LY231617, an antioxidant known to exert neuroprotection in rats
subjected to global ischemia. Since delayed neuronal death has the
characteristics of apoptosis, we speculate that clone 17a may be
involved in apoptosis. We examined the expression level of clone 17a in
in vitro models of apoptosis using cerebellar granule
neurons that were subjected to potassium removal, glutamate toxicity,
or 6-hydroxydopamine treatment and found that clone 17a transcripts
were induced in cerebellar granule neurons by glutamate or
6-hydroxydopamine stimulation but not potassium withdrawal.
 |
INTRODUCTION |
A short period of global cerebral ischemia in rodents causes
neurons in the striatum, hippocampus, and lateral thalamus to die (1).
Intriguingly, pyramidal neurons in the CA1 region of the hippocampus
undergo delayed neuronal death 3-5 days after the insult (1, 2). A
similar phenomenon occurs in human cerebral ischemia (3). This time lag
provides a window of opportunity for therapeutic interventions after
ischemic injury. However, the molecular mechanisms that trigger and
lead to delayed neuronal death have not been well established, although
many hypotheses have been proposed such as excitotoxicity of glutamate,
disturbed calcium homeostasis, altered lipid metabolism, free radicals, and mitochondrial involvement (for reviews, see Refs. 4 and 5). There
is a growing body of evidence suggesting that apoptotic events occur in
both global and focal brain ischemia (6-8). It is possible that many
of these hypotheses may in fact represent different aspects of a common
mechanism. One of the approaches that can be used to further our
understanding of the molecular mechanism of delayed neuronal death is
to establish the gene expression profile of the process. Differential
expression of many genes has been observed in ischemic brains,
including some immediate early genes, heat shock proteins, and factors
controlling apoptosis such as Bcl2, Bcl-x, Bax, and caspases (for
reviews, see Refs. 9 and 10).
Differential display (DD)1 is
a technique based on reverse transcription (RT) and PCR (11) and is
widely used for identifying genes with altered expression in
pathological and special physiological conditions. It has been used
successfully in the discovery of several differentially expressed
sequences in rodent models of cerebral ischemia. Tsuda et
al. (12, 13) discovered two genes, serine protease inhibitor,
SPI-3, and zinc transporter gene, ZnT-1, up-regulated in gerbil hippocampi 24 h after 5 min of carotid occlusion. Wang and co-workers (14, 15) detected adrenomedullin induction using RNAs isolated from rat ipsilateral cortex 2h and 12 h after permanent middle cerebral artery occlusion. In our study, we used a rat model of global cerebral ischemia induced by 30 min of four-vessel occlusion (4VO). Since we are interested in gene
induction prior to severe neuronal damage, and it is known that
histological evidence of neuronal damage in the CA1 region of this
model is not observed at 24 h after reperfusion (16), we used
total RNA isolated at 24 h post-ischemia for differential display analysis.
 |
EXPERIMENTAL PROCEDURES |
Animals--
Transient forebrain ischemia was induced by the
4VO treatment as described by Pulsinelli and Brierley (17). Briefly,
Wistar rats (Hilltop Labs, Scottsdale, PA) were prepared for forebrain ischemia by electrocauterizing the bilateral vertebral arteries and
placing atraumatic clasps around the common carotid arteries without
interrupting the arterial blood flow. Rats were anesthetized for the
whole procedure using 2% halothane inhalation. On the following day,
forebrain ischemia was induced by tightening the clasps for 30 min. In
the case of sham-treated animals, the carotids were exposed but not
occluded. Body temperature was maintained at 37 °C for 1 h
during and after the 4VO treatment by means of heat lamps. Animals were
sacrificed by decapitation at 24, 48, and 72 h after ischemia or
sham operation. All animal procedures were performed in accordance with
institutional guidelines. Compound LY231617 (Lilly) was given orally 30 min before 4VO and again 4 h after 4VO at a dose of 50 mg/kg.
Control rats received 2% acacia vehicle.
Cultured Rat Cerebellar Granule Neurons (CGN)--
Primary
cultures of CGNs were prepared from 8-day-old-Harlan Sprague-Dawley rat
pups (Harlan Breeders, Indianapolis, IN) as described by Gallo et
al. (18). Cells were dissociated from freshly dissected cerebella
by mechanical disruption in the presence of trypsin and DNase (Sigma)
and were resuspended in basal medium, Eagle's (Life Technologies,
Inc.), supplemented with 10% fetal bovine serum, 25 mM
KCl, and 0.1 mg/ml gentamicin (Life Technologies, Inc.). Cells were
seeded at a density of 1.2-1.5 × 106 cells/ml on
poly-L-lysine-coated dishes. Cytosine arabinoside (10 µM; Sigma) was added to the culture medium 24 h
after initial plating to arrest the growth of non-neuronal cells.
Cultures were maintained at 37 °C in a humidified incubator with
95% air, 5% CO2 and were fed with glucose (10 mM) after 7 days in vitro and thereafter every
4th day. Cultures generated by this method have been shown to contain
95% granule neurons (19). In all experiments, neurons were used after
being cultured 7-8 days in vitro. For low
K+-induced neuronal apoptosis, the concentration of KCl in
the conditioned medium was switched from 25 to 5 mM for an
overnight treatment. For glutamate-induced apoptosis, CGNs were treated
with glutamate (Sigma) at a final concentration of 30 µM
in a 12-well plate (3.8 cm2/well) and incubated overnight.
In a separate experiment, CGNs were treated with 50 µM
6-hydroxydopamine (6-OHDA) (Research Biochemicals, Natick, MA) overnight.
Oligonucleotides and Peptide Synthesis--
Oligonucleotides
were custom-synthesized by Genosys Corp. (The Woodlands, Texas).
Peptide synthesis and rabbit antibody production was provided by
Genemed Synthesis, Inc. (South San Francisco, CA).
Total RNA Isolation--
Total RNA was isolated from eight 4VO-
and eight sham-treated animals. The region of the dorsal hippocampus
containing the CA1 layer was carefully dissected from the remainder of
the hippocampus, immediately frozen in liquid nitrogen, and stored at
80 °C. Total RNA was isolated using the RNAgents® total RNA
isolation system (Promega Corp., Madison, WI) following the
manufacturer's instructions.
Differential Display--
To remove DNA contamination, 5 µg
of total RNA from each animal was incubated at 37 °C for 30 min with
1 unit of amplification grade RNase-free DNase I (Life Technologies,
Inc.) in 10 mM Tris-HCl, pH 7.5, and 10 mM
MgCl2. The DNA digestion was terminated by addition of 1 µl of 0.5 M EDTA and 3 µl of 2 M sodium
acetate per 50-µl reaction. RNA was then phenol-extracted and
precipitated (20).
For first strand cDNA synthesis, total RNA (2 µg) pooled from
four animals was used for each reaction. The reaction contained 20 pmol
of T12G, T12C, or T12A as primers. Other reagents were obtained from
the SuperScript II RT kit (Life Technologies, Inc.).
The DD-PCR was performed with 20 ng of first strand cDNA, 20 pmol
of each primer, 20 pmol of each dNTP, 1 µCi of
[
-33P]dATP (NEN Life Science Products), PCR buffer
containing 1.5 mM MgCl2, and 1 unit of
AmpliTaq® DNA polymerase (Perkin-Elmer) per 20-µl reaction. The
arbitrary primer used in this study was 5'-AATCGGGCTG-3'. Oligo(dT)
primers were the same as those used in the first strand cDNA
synthesis. Thermocycles were performed in a Peltier Thermal Cycler,
PTC-225 (MJ Research, Inc., Watertown, MA) as follows: 92 °C, 2 min;
40 times (92 °C, 15 s; 40 °C, 2 min; ramp to 72 °C in 1 min; 72 °C, 1 min); 72 °C, 5 min and kept at 4 °C thereafter
until further processed.
The PCR products were incubated with 15 µl of loading buffer at
95 °C for 2 min. Samples, 3 µl each, were electrophoresed at 1700 V on a 6% polyacrylamide gel containing 8.3 M urea until the xylene cyanol marker reached the bottom. After immobilizing the gel
on Whatman 3MM paper and drying for 30 min under vacuum at 80 °C,
the gel was exposed to a Biomax MR film (Eastman Kodak Co.) overnight.
The intensity of the bands on the x-ray film is indicative of
expression levels of the transcripts. Differentially expressed bands
were observed between 4VO- and sham-treated animals. The DD-PCR was
repeated with the primer pairs that detected the differential
expression. To achieve higher resolution, PCR products containing bands
with the confirmed difference were electrophoresed on a 60-cm-long
polyacrylamide gel using a genomyxLR high-throughput sequencer (Genomyx
Corp., Foster City, CA). The bands of interest were excised and
immersed in 100 µl of 10 mM Tris buffer containing 1 mM EDTA, pH 8.0. The DNA was eluted by cycles of freezing,
thawing, and vortexing. Five µl of eluted DNA was amplified with 60 pmol of each primer used for DD-PCR, PCR buffer, 6 nmol of each dNTP, and 2.5 units of AmpliTaq Gold® DNA polymerase (Perkin-Elmer) per
60-µl reaction. Thermocycles were performed in a Peltier Thermal Cycler, PTC-225 (MJ Research, Inc., as follows: 92 °C, 15 min; 40 times (92 °C, 15 s; 40 °C, 2 min; ramp to 72 °C in 1 min;
72 °C, 1 min); 72 °C, 10 min and kept at 4 °C thereafter until
further processed. The PCR products were purified with the QIAquick PCR purification kit (Qiagen Inc., Chatsworth, CA) and ligated with pCR 2.1 vector using the original TA cloning kit (Invitrogen Corp., Carlsbad,
CA). The plasmids were transformed into MAX Efficiency DH5
or DH10B
competent cells (Life Technologies, Inc.) according to the
manufacturer's instructions. Cells were incubated at 37 °C for
18 h in Magnificent Broth (MacConnell Research Corp., San Diego,
CA) containing 100 µg/ml ampicillin. Plasmid DNAs were purified using
the QIAwell ultra plasmid kit (Qiagen). Clones that contained inserts
were submitted for automated DNA sequencing (Lilly DNA Technology
group, Indianapolis, IN). The nucleic acid and deduced peptide
sequences were searched in GenBankTM and GenEMBLTM data
bases using the FastA and BLAST algorithms provided in the Genetics
Computer Group (GCG) software package (21).
Northern Blot Analysis--
Northern blotting was carried out
as described originally by Alwine et al. (22) with
modifications. Ten µg of each RNA sample and 10 µg of 0.24-9.5-kb
RNA ladder (Life Technologies, Inc.) was denatured and subjected to
electrophoresis on 1.2% agarose gels containing 2.2 M
formaldehyde. The gels were routinely stained with ethidium bromide to
visualize the RNA ladder and to verify that each lane contained similar
amounts of undegraded rRNAs. RNA was transferred onto Zeta-Probe GT
nylon membranes (Bio-Rad) at 160 V in 50 mM Tris buffer
containing 45 mM boric acid and 0.5 mM EDTA for
1 h at 4 °C and cross-linked by baking at 80 °C in vacuum
for 30 min.
The insert of clone 17a was released from pCR 2.1 with
EcoRI, separated on agarose gel, excised, and extracted with
the Prep-A-Gene kit (Bio-Rad). Labeling was performed with 50 µCi of
[
-32P]dCTP (Amersham Pharmacia Biotech) per 20-µl
reaction using the random primed DNA labeling kit (Roche Molecular
Biochemicals). Hybridizations were performed in 50% formamide, 0.12 M Na2HPO4, 0.25 M NaCl,
and 7%(w/v) sodium dodecyl sulfate (SDS) at 43 °C overnight. The
blots were washed twice, each for 10 min, at room temperature in 30 mM sodium citrate buffer, pH 7.0, containing 0.3 M NaCl and 0.1% SDS. A third wash was conducted at
65 °C, for 10 min, in 3 mM sodium citrate buffer, pH
7.0, containing 30 mM NaCl and 0.1% SDS. To check RNA
loading in each lane, some membranes were stripped and rehybridized
with probes synthesized from a human actin cDNA
(CLONTECH, Palo Alto, CA).
Rapid Amplification of cDNA Ends (RACE)--
DNA sequences
at the 5' and 3' ends of clone 17a cDNAs were determined by RACE
using the rat brain Marathon-Ready cDNA (whole brains pooled from
normal Harlan Sprague-Dawley males, 10-12 weeks of age;
CLONTECH). Briefly, a 25-µl PCR reaction
contained the clone 17a-specific primer (0.2 µM), the
CLONTECH adaptor primer (0.2 µM),
0.25 ng of Marathon-Ready cDNA, KlenTaq PCR reaction buffer, dNTPs
(0.2 mM each), and Advantage KlenTaq polymerase mix
(CLONTECH). Thermocycles were programmed as
follows: 94 °C, 1 min; 5 times (98 °C, 10 s and 72 °C, 1 min); 5 times (98 °C, 10 s and 70 °C, 1 min); 25 times
(98 °C, 10 s and 68 °C, 1 min); 68 °C, 2 min and kept at
4 °C thereafter until further processed. The sense primer
5'-GAGAGATGGCTCAGCGGTTAAGAGCAC-3' was used as the gene-specific primer
2 (GSP2) for 3'-RACE. The antisense primer 5'-GAAGAGGGCATCAGATCTC-ATTACAGATGG-3' was used as GSP1 for 5'-RACE. The
amplification products were electrophoresed on 4% agarose gels and
transferred to a Zeta-Probe GT membrane (Bio-Rad) for Southern blot
analysis. Biotinylated 5'-CCCAGCAACCACATGGTGGCTCACAACC-3', a sequence
between GSP1 and GSP2, was used as a probe for Southern blot analysis.
The RACE products corresponding to the specific bands on the Southern
blot were extracted from the agarose gel matrix with the Prep-A-Gene
DNA purification kit (Bio-Rad), ligated into a pCR2.1 vector
(Invitrogen), and transformed into Max Efficiency DH5
competent
cells (Life Technologies, Inc.). Ampicillin-resistant colonies were
characterized by PCR amplification with a variety of primer
combinations and DNA sequencing.
In Situ Hybridization--
For in situ
hybridization, five 4VO- and five sham-treated animals were examined.
Rat forebrains were rapidly frozen in isopentane chilled with dry ice
and serially sectioned at
20 °C in the coronal planes throughout
the rostral-caudal axis of the hippocampus. Sixteen-micron-thick
sections were thaw-mounted onto gelatin-coated slides and stored at
80 °C until processed for in situ hybridization. Regions evaluated included only those that contained the same coronal
sections of the dorsal hippocampus. BamHI-EcoRI
fragments of clone 17a were constructed by the expand high fidelity PCR system (Roche Molecular Biochemicals). The 131-bp fragments were inserted into the plasmid vector pT7/T3-18 (Ambion, Austin, TX) with T4
DNA ligase (Life Technologies, Inc.). Vectors containing the insert
were linearized with EcoRI or BamHI separately at
37 °C, purified with the QIAquick PCR purification kit (Qiagen), and
used as the templates to synthesize the probes. Single-stranded RNA
probes were synthesized in the presence of 35S-UTP using
the riboprobe in vitro transcription system (T3/T7; Promega). Antisense and sense RNA probes were transcribed with either
T3 or T7 RNA polymerase corresponding to the promoter region flanking
the insert sequence in the T3/T7-18 vector. After in vitro
transcription, RNA probes were treated with RNase-free DNase I to
remove the template DNA.
The hybridization was conducted with the SureSite hybridization
reagents kit (Novagen, Inc. Madison, WI) following the manufacturer's instructions. Briefly, frozen tissue sections were fixed with 4%
paraformaldehyde for 20 min and permeabilized with 1 µg/ml proteinase
K for 10 min at room temperature. Each slide was covered with 80 µl
of hybridization buffer containing 107 cpm of RNA probes.
Hybridization was performed for 18 h at 50 °C in a humidified
chamber. Background controls were performed on 4VO sections using the
sense RNA as a probe. For experimental controls, sections of
sham-operated animals were hybridized with the antisense probe. After
hybridization, unbound probes were digested with RNase A (20 µg/ml)
for 30 min at 37 °C. The post-hybridization washes were all
performed at 50 °C. Air-dried slides were exposed to
Hyperfilm-
MAX x-ray film (Amersham Pharmacia Biotech) for 1 h
and developed manually in Kodak developer D-19. For higher resolution, sections were covered with 50% Kodak NTB-2 emulsion and
exposed for 2.5 h in the dark. The slides were developed, counter-stained with hematoxylin and eosin (H&E), mounted with paramount, and photographed using both light- and dark-field microscopy.
 |
RESULTS |
Identification of Clone 17a--
To identify differentially
expressed genes in response to transient cerebral ischemia, poly(A)
RNAs prepared from the dorsal hippocampus of 4VO- and sham-operated
rats were compared by differential display analysis. We detected both
up- and down-regulated transcripts. However, we focused on an
ischemia-induced transcript, clone 17a. Fig.
1 displays the result of DD-PCR that
contained clone 17a. The products from each DD-PCR reaction were loaded
in two lanes. Each lane contained 70-150 bands. Interestingly, the
arbitrary primer sequence was found at both ends of the amplified
fragment of clone 17a (Fig. 2).
Apparently, the same random primer was used as both 5' and 3' primers
in the DD-PCR, and the anchored oligo(dT)primer was left unused.
Conceivably, amplification of clone 17a fragments occurred in all
DD-PCR reactions containing the random primer 5'-AATCGGGCTG-3', no
matter which oligo(dT) primer was used.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 1.
Identification of clone 17a, whose expression
was up-regulated in ischemic rats. Total RNA was isolated from CA1
regions in hippocampi of 4VO- and sham-operated rats. RNAs from every
four animals were combined for the first strand cDNA synthesis.
cDNA was generated with an anchored primer, T12C, and used as the
template for PCR amplification. The products from each PCR reaction
were resolved in two adjacent lanes on a 6% polyacrylamide gel
containing 8.3 M urea. Total eight 4VO and eight sham
animals were used in DD-PCR. The arrow indicates the PCR
fragments of clone 17a. The numbers on the left
margin refer to size markers in bases (b).
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
Nucleotide sequence of clone 17a. The
sequence of the arbitrary primer used in differential display analysis
is in bold type. GSP1 and GSP2 (underlined) were
paired with the adaptor primer used in 5'- and 3'-RACE, respectively.
The direction of primer extension is indicated by the
arrows.
|
|
Northern Blot Analysis--
To confirm the gene expression
patterns observed in differential display analysis, the clone 17a
fragment was used as the template for probe synthesis in Northern blot
analysis. Clone 17a transcripts showed an approximately 35-fold
increase in 4VO animals versus sham (Fig.
3). The size range of the transcripts was
160-350 bases. Data base search of clone 17a in GenBankTM
and GenEMBLTM using the BLAST and FastA programs revealed
regions of homology to rodent B2 sequences and a rat
somatotropin intron. To check whether somatotropin mRNA is elevated
in the 4VO rat, the fifth exon (1909-2109) of rat presomatotropin gene
(GenBankTM accession number J00740 or V01238) was used as a
probe for Northern blot analysis. Hippocampal total RNA was loaded, 10 µg per lane, and probed with 32P-labeled fifth exon
fragments generated by PCR. A higher level of somatotropin expression
was not observed in 4VO rats (data not shown). On the other hand,
B2 sequences are believed to be spread throughout the
genome by retrotransposition and are found in both introns and exons of
other genes (23).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 3.
Expression levels of clone 17a transcripts
upon ischemic insult. Total RNA was loaded, 10 µg per lane, and
electrophoresed on a 1.2% agarose gel. Separated RNAs were transferred
to a nylon membrane and hybridized with 32P-labeled clone
17a fragments (upper panel) and -actin as a loading
control (lower panel). Each lane contained RNAs isolated
from four animals. The numbers on the left margin
refer to size markers in kilobases (kb).
|
|
Clone 17a Matches Characteristics of B2
Sequences--
To get full-length cDNA, the sequence of clone 17a
obtained from DD-PCR was used to design primers for 5'- and 3'-RACE
(Fig. 2). The 5'-RACE was conducted using GSP1. Heterogeneity at the 5'
end was observed in both length and base composition (data not shown);
however, the consensus sequences started at GAGATG (Fig. 2). By using
GSP2, the 3'-RACE produced multiple sequences as well (Fig.
4). Sequence alignment using GCG software
showed a consensus sequence of about 160 bases. Most of the RACE
sequences contained open reading frames (ORF) of either 29- or 40-amino acid peptides. Further analysis of these transcripts revealed promoter
regions, box A and B (24), of RNA polymerase III (polIII) within the
transcripts. The poly(A) addition signal, transcription stop sequence,
and poly(A) tail was found at the ends of most 3' sequences. The
sequence results indicate that the transcripts are products of polIII
and match the characteristics of rodent B2 sequences.

View larger version (66K):
[in this window]
[in a new window]
|
Fig. 4.
Sequences obtained by 3'-RACE matched the
characteristics of polIII transcripts. Box A and
B are promoter regions for polIII, which reside within the
transcripts. Dark shaded bases are invariant in all non-5 S
genes transcribed by polIII. Light shaded bases are
invariant in all tRNAs. Transcriptional stop signals are
underlined bases. Poly(A) addition signals are
underlined. Some sequences contained nested poly(A) addition
signals. The letters and numbers on the
left margin refer to isolated clones from 3'-RACE except the
last row where clone 17a was obtained from DD-PCR.
|
|
Hypothetical Peptide--
The ORFs seen in clone 17a gene family
suggest that peptides could be generated by these sequences. Proteins
coded by small open reading frames (<100 amino acids) belong to a
number of important categories, such as ATPase modulators, stress
proteins, transcriptional regulators, and antioxidants (for review, see
Ref. 25). To see whether the clone 17a gene is translated, a rabbit
polyclonal antibody was generated against the synthetic peptide
CSSRGHEFNSQQPHGGSQPSVKRSD deduced from the clone F3 sequence (Fig. 4).
The full-length peptide is predicted to have a molecular mass of 4.4 kDa and an isoelectrical point of 8.7. To search for the hypothetical
peptide, proteins were extracted from the hippocampus of 4VO and sham
rats and analyzed, 80 µg per lane, by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western
blotting. The peptide was not detected by the antibody raised against
the synthetic peptide. Transfection of 293 cells with the clone F3
sequence in a pcDNA3.1 vector yielded no detectable peptide
expression. To date, translation of B2 sequences has not
been reported.
Clone 17a Transcripts Are Localized in Pyramidal Neurons--
To
examine the tissue-specific expression of clone 17a in rat brain, an
antisense riboprobe was transcribed from clone 17a and hybridized with
rat brain sections. After x-ray film exposure, strong expression was
detected mainly in the CA1 region of 4VO hippocampi (Fig.
5A). Some expression was
observable in the cortex of 4VO brains as well. Brain sections of
sham-treated rats showed a background level expression with the
antisense probe (Fig. 5B). The specificity of the
hybridization reaction was confirmed by comparison of signals generated
from the antisense probe (Fig. 5A) and the sense probe (Fig.
5C) on 4VO brain sections. By using emulsion, higher
resolution (1000×) was achieved (Fig.
6). In the CA1 region of a 4VO
hippocampus, silver grains were found in the cytoplasm of pyramidal
neurons. Since sections were counter-stained with H&E, nuclei are shown
as dark gray areas in the bright-field image. In dark-field microscopy,
silver grains reflect light and are shown as bright particles in a dark
background. In the same brain region of sham animals, silver grains
were also observed around nuclei but with a much less density. The same
observation was made in brain sections derived from five individual
animals. This result confirms the differential expression of clone 17a in 4VO rats discovered by RT-PCR and Northern blot analysis and is
consistent with the fact that B2 poly(A) RNAs are mainly
distributed in the cytoplasm (26).

View larger version (89K):
[in this window]
[in a new window]
|
Fig. 5.
In situ hybridization of clone 17a
in brain sections of 4VO and sham animals. Antisense and sense
probes were in vitro transcribed from clone 17a DNA in
presence of 35S-UTP. Expression of transcripts in brain
sections of 4VO and sham animals was visualized on x-ray films.
A, a 4VO brain section hybridized with the antisense probe.
B, a brain section of sham-treated animal probed with the
antisense probe. C, a 4VO brain section hybridized with the
sense probe. These results were replicated with brain sections from
five separate animal experiments.
|
|

View larger version (116K):
[in this window]
[in a new window]
|
Fig. 6.
Expression of clone 17a in the CA1 regions of
hippocampi. Brain sections from 4VO- and sham-treated rats were
in situ hybridized with the 35S-labeled
antisense riboprobes derived from the clone 17a DNA fragment. The
sections were covered with 50% Kodak NTB-2 emulsion, exposed for
2.5 h in the dark, and counter-stained with H&E. The CA1 regions
were photographed with both light- and dark-field microscopy. Clone 17a
transcripts were visualized as the light grains in the dark-field
images. These results were replicated with brain sections from five
separate animal experiments. Magnification, × 1000.
|
|
Animals Treated with LY231617--
The antioxidant LY231617 has
been shown to reduce delayed neuronal death in the CA1 region (27).
Although LY231617 possesses antioxidant activity as one of its
properties, the precise mechanism through which LY231617 prevents
neuronal injury after global ischemia is not clear. To establish that
clone 17a gene is closely related to delayed neuronal death, rats were
treated with the compound as described above. At 24 h
post-ischemia, compound-treated animals had a background level
expression of clone 17a much less than those of untreated 4VO rats
(Fig. 7). This result suggests that clone
17a expression was closely associated with neuronal degeneration. The
same blot also demonstrates that a higher level expression of clone 17a
occurred around 24 h post-ischemia and was not observed at 72 h post-ischemia (Fig. 7). Decreased expression of clone 17a beyond
24 h post-ischemia was also observed in the CA1 region probed with
the antisense RNA (Fig. 8), which
suggests that induction of clone 17a transcripts was an early event in
delayed neuronal death. Interestingly, an increasing amount of
B2 transcripts in the dentate gyrus was detected over the
same period (Fig. 8).

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 7.
The effect of antioxidant LY231617 on the
expression of clone 17a. The upper panel shows the
autoradiograph of Northern blot analysis. Animals were either treated
with antioxidant LY231617 (T, treated) or used as controls
(U, untreated with the antioxidant but received 2% acacia
vehicle). LY231617 was given orally 30 min before 4VO and again 4 h after the 4VO treatment at a dose of 50 mg/kg. Animals were
sacrificed at either 24 or 72 h post-ischemia. Each lane contains
10 µg of hippocampal RNAs. The blot was hybridized with the
32P-labeled clone 17a probe. The lower panel
shows 18 S ribosomal RNAs stained with ethidium bromide as a loading
control. The size marker on the left margin is given in
bases (b).
|
|

View larger version (76K):
[in this window]
[in a new window]
|
Fig. 8.
Expression of clone 17a at various time
points after reperfusion. The antisense probe was transcribed
in vitro from clone 17a DNA in the presence of
35S-UTP and was in situ hybridized with brain
sections of 4VO rats sacrificed at different time points after ischemia
as indicated. Expression of transcripts was visualized on x-ray films.
These results were replicated with brain sections from three separate
animal experiments.
|
|
Clone 17a Was Induced by Glutamate and 6-OHDA in
CGNs--
Delayed neuronal death has the morphological and
biochemical characteristics of apoptosis (6, 8, 28). We postulated that
clone 17a may be involved in apoptosis. B2 induction has been observed in the apoptotic cell death of PC-12 cells upon nerve
growth factor deprivation (29). To investigate the possible involvement
of clone 17a in apoptosis, in vitro models of neuronal apoptosis in cultured CGNs were examined for the expression of clone
17a. CGNs from early postnatal rats can be maintained in the culture
medium containing serum and high potassium (25 mM) (30).
The apoptotic cell death of cultured CGNs can be induced by switching
potassium to a lower but more physiological concentration (5 mM) (31). Relatively low concentrations of glutamate or
6-OHDA, as applied in this study, are also causative factors of CGN
apoptosis (32, 33). Glutamate is a known potent excitotoxin critical for the neuronal damage in ischemic stroke (34). 6-OHDA is proposed to
be the endogenous toxin involved in the neuronal damage of Parkinson's
disease (35). In contrast to low K+ model,
glutamate-induced apoptosis does not require RNA or protein synthesis
but does require post-translational activation (32).
In Northern blot analysis, total RNA isolated from apoptotic and
control CGNs was loaded 10 µg per lane. Induction of clone 17a
transcripts was found most significant in the glutamate- and 6-OHDA-induced cell death (Fig. 9,
lanes 3 and 4). However, a higher expression
level of clone 17a was not detected in the low K+-induced
cell death (Fig. 9, lane 2). It is known that apoptosis of
CGNs can be induced by different stimuli and environmental conditions
and that different intracellular mechanisms are likely to be involved
(36). Results in this study indicate that B2 expression was
associated with certain types of apoptosis. Since it is easy to detect,
B2 sequences could be used as a marker to detect or
distinguish different types of cell death. Further experiments are
needed to establish its specific expression in apoptosis and whether it
is apoptotic or protective in delayed neuronal death.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 9.
Northern blot analysis of clone 17a
expression in cultured CGNs. CGNs were cultured as described under
"Experimental Procedures." Total RNA was isolated and loaded 10 µg per well on a 1.2% agarose gel. The separated RNAs were
transferred to a nylon membrane and probed with the
32P-labeled clone 17a fragments (upper panel).
Lane 1, cultured CGNs without a special treatment were used
as a control. Lane 2, CGNs were treated with 5 mM KCl in the conditional medium overnight. Lane
3, CGNs were treated overnight in 30 µM glutamate.
Lane 4, CGNs were treated with 50 µM 6-OHDA
overnight. The same blot hybridized with the -actin probe is shown
as a loading control (lower panel). The size marker on the
left margin is presented in bases (b).
|
|
 |
DISCUSSION |
The primary goal of this study is to identify genes involved in
ischemic cell death in the rat 4VO model. We are interested, specifically, in early gene products that mediate or control delayed neuronal death. The rats that we used in this study were sacrificed 24 h after the 4VO treatment. At this time point, there is no histological evidence of CA1 neuronal damage (16). Extensive neuronal
damage occurs at 72 h after ischemia.
In mammalian genomes, there are families of highly repeated DNA
sequences, including long and short interspersed elements (37).
B2 sequences are a family of short interspersed elements consisting of about 105 related sequences dispersed
throughout the genome (23, 38). The consensus region of B2
sequences is 180 bp long and contains the RNA polymerase III promoter,
poly(A) addition signal, and transcription stop signal (24). A member
of the B2 family deviates 3-5% in the consensus region
(38). Sequences at the 3' end following the consensus sequence are most
variable. On Northern blots, B2 sequences are generally
displayed as a smear in the range of 200-600 bp (39). The function of
B2 sequences has not been established, although a general
regulatory role in gene expression and RNA processing has been
suggested (38). The RACE products of clone 17a contained multiple
sequences with variable 5'- and 3'-flanking regions and possessed all
the structural characteristics of B2 sequences. Northern
blot analysis showed that the size range of clone 17a expressed in 4VO
rats was between 160 and 540 bp. Sequence analysis revealed that the
RACE products contained the internal promoter regions of polIII and a
consensus region of approximately 160 bp with less than 4% deviation.
The length of the poly(A) tail obtained by RACE is not the authentic
length of poly(A) tail but the length of the oligo(dT) primer used for
first strand cDNA synthesis. Although these transcripts contained
ORFs, the translated product was not detected. B2 poly(A)
RNAs are believed to be the final functional products involved in
regulation of mRNA processing, transport, stability, and
translation (26, 40, 41). In situ hybridization demonstrates
that these transcripts were predominantly located in the neurons within
the hippocampal CA1 region, indicating that B2 sequences
may be closely related to the distinct effect of 4VO on pyramidal
neurons. The specific association of B2 sequences in
delayed neuronal death was further manifested in LY231617-treated 4VO
animals, where the compound-protected neurons in the CA1 region showed
background levels of clone 17a transcripts.
Although expression of many genes is found to be altered during
ischemic injury (10), the mechanism of delayed neuronal death is still
vague. Many histological and biochemical observations in delayed
neuronal death match features of apoptosis (6, 8, 28). Induction of
several regulatory genes of apoptosis is associated with delayed
neuronal death. For example, both mRNA and protein of Bax are
expressed prior to delayed neuronal death in the CA1 region (42, 43).
The anti-apoptotic gene bcl-2 is expressed in neurons that
have survived delayed neuronal death (44). Increased levels of nuclear
factor
B in the nuclei of pyramidal neurons are observed after
ischemic injury (45). Nuclear factor
B has been shown to both
promote (46) and suppress (47) apoptosis depending on conditions and
cell types. Finally, caspase-3 and other caspase activities are also
observed in delayed neuronal death (8). The finding that clone 17a was
expressed in the glutamate- and 6-OHDA-induced apoptosis of CGNs is a
suggestion of B2 involvement in apoptosis and further
indicates that delayed neuronal death was mediated by apoptosis.
However, whether B2 sequences promote neuronal apoptosis or
protect neurons from delayed neuronal death needs further
investigation. Since the amount of clone 17a transcripts decreased at
48 and 72 h in situ (Fig. 8) while cell death increases
in the same time frame (16), high expression of the transcripts at
24 h post-ischemia is unlikely the consequence of cell death. It
is known that DNA fragmentation caused by methyl methanesulfonate does
not induce B2 expression (48). The differences in clone 17a
expression among the low K+-, glutamate-, and
6-OHDA-induced cell death in CGNs may be due to the severity of
apoptosis or may reflect the differences in their apoptotic pathways.
It is known that glutamate- or 6-OHDA-induced apoptosis in CGNs is
p53-dependent (49, 50) and involves loss of mitochondrial
function (51, 52), whereas low K+-induced apoptosis is
p53-independent (53) and does not depend on a loss of mitochondrial
function (54). It would be of interest to know whether B2
sequences play a specific role in the apoptotic cascade and whether
altered B2 expression can affect apoptosis.
B2 expression can be stimulated under various conditions.
The level of B2 transcripts is high in early embryos (40,
55) and virally transformed cells (56) and is low or absent in
differentiated cell types (57). Transcription of B2
sequences can be induced in somatic cells by heat shock (58, 59) and
serum stimulation (60). Interestingly, apoptosis has been observed
under similar circumstances (61, 62). B2 sequences are
transcription products of polIII. The possible involvement of
B2 sequences in apoptosis can be unveiled further by
examining induction of polIII activity in various viral
transformations. Adenovirus E1A (63), simian virus 40 T antigens (64),
X-protein of the human hepatitis B virus (65), and Tax protein of the
human T-cell leukemia virus type 1 (66) are known to trigger apoptosis
in mammalian cells. On the other hand, cells transformed with these
agents exhibit an increased level of polIII transcripts (67-70).
During transcription of B2 sequences, polIII activity is
modulated by transcription factors TFIIIB and TFIIIC (71). The rapid
increase in B2 RNA levels is most likely mediated by these factors. SV40 T antigen is a transactivator of polIII (72), which
increases activity of TFIIIC by changing its abundance or phosphorylation state (73). TFIIIC has been shown to be the rate-limiting factor in the formation of polIII initiation complexes (71) and probably the target of trans-activators (74). The ability of
X-protein to activate polIII is due to its interaction with TFIIIB
rather than TFIIIC (69). During X-protein activation, polIII catalytic
activity remains unchanged. TFIIIB is also the target of Tax, which
enhances polIII transcription by increasing the effective concentration
of TFIIIB (70). However, further studies will be required to determine
the upstream activator of clone 17a transcription and its mode of
activation in the rat hippocampus after the 4VO treatment.
The action of B2 sequences can be predicted from their
ability to serve as retroposons (75) and to interact with mRNAs
(41). B2 sequences are found to be a cis-acting regulator
of gene expression (76). Insertion of Alu sequences, the human
counterpart of B2 sequences, found in the coding region of
caspase-8 in tumor cells reduces the effect of the protein on apoptosis
(77). B2 poly(A) itself could play a role in selective
inhibition of mRNA translation (78). B2 sequences may
also regulate the stability of certain RNAs, such as mRNAs of
c-Fos, c-Myc, and tumor necrosis factor (41). All these could serve as
important mechanisms for gene regulation in delayed neuronal death.
Induction of short interspersed elements in mouse, rabbit, and human
suggests that these sequences serve a common function in the mammalian
system (59). Their expression could be part of a defensive mechanism.
This study suggests a new direction for seeking the function of
B2 sequences and may facilitate our effort in elucidating
the mechanism of delayed neuronal death in ischemic injury.
 |
ACKNOWLEDGEMENTS |
We are grateful to Barry Smalstig for
providing 4VO animals. We thank Bradley S. DeHoff and Chris Mundy for
their expert technical assistance. We also thank Melvyn Baez for
critical reading of the manuscript.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF168585, AF168586, AF168587, AF168588, AF168589, AF168590,
AF168591, AF168592, AF168593, AF168594, AF168595, and AF168596.
Present address: Astra Arcus, Inc., 1 Innovation Dr., Worcester,
MA 01605.
§
To whom correspondence should be addressed: Drop Code 0434, Neuroscience Research Division, Eli Lilly and Co., Indianapolis, IN
46285. Tel.: 317-276-3506; Fax: 317-276-1414; E-mail:
Little_Sheila_P@lilly.com.
 |
ABBREVIATIONS |
The abbreviations used are:
DD, differential
display;
4VO, four-vessel occlusion;
6-OHDA, 6-hydroxydopamine;
bp, base pair(s);
CGN, cerebellar granule neurons;
GSP, gene-specific
primer;
H&E, hematoxylin and eosin;
kb, kilobase(s);
ORF, open reading
frame;
PCR, polymerase chain reaction;
polIII, RNA polymerase III;
RACE, rapid amplification of cDNA ends;
RT, reverse transcription;
TF, transcription factor.
 |
REFERENCES |
| 1.
|
Pulsinelli, W. A.,
Brierley, J. B.,
and Plum, F.
(1982)
Ann. Neurol.
11,
491-498[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Kirino, T.
(1982)
Brain Res.
239,
57-69[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Petito, C. K.,
Feldmann, E.,
Pulsinelli, W. A.,
and Plum, F.
(1987)
Neurology
37,
1281-1286[Abstract/Free Full Text]
|
| 4.
|
Abe, K.,
Aoki, M.,
Kawagoe, J.,
Yoshida, T.,
Hattori, A.,
Kogure, K.,
and Itoyama, Y.
(1995)
Stroke
26,
1478-1489[Abstract/Free Full Text]
|
| 5.
|
Juurlink, B. H.,
and Sweeney, M. I.
(1997)
Neurosci. Biobehav. Rev.
21,
121-128[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Heron, A.,
Pollard, H.,
Dessi, F.,
Moreau, J.,
Lasbennes, F.,
Ben-Ari, Y.,
and Charriaut-Marlangue, C.
(1993)
J. Neurochem.
61,
1973-1976[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Honkaniemi, J.,
Massa, S. M.,
Breckinridge, M.,
and Sharp, F. R.
(1996)
Brain Res. Mol. Brain Res.
42,
79-88[Medline]
[Order article via Infotrieve]
|
| 8.
|
Chen, J.,
Nagayama, T.,
Jin, K.,
Stetler, R. A.,
Zhu, R. L.,
Graham, S. H.,
and Simon, R. P.
(1998)
J. Neurosci.
18,
4914-4928[Abstract/Free Full Text]
|
| 9.
|
MacManus, J. P.,
and Linnik, M. D.
(1997)
J. Cereb. Blood Flow Metab.
17,
815-832[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Koistinaho, J.,
and Hokfelt, T.
(1997)
Neuroreport
8,
1-8
|
| 11.
|
Liang, P.,
and Pardee, A. B.
(1992)
Science
257,
967-971[Abstract/Free Full Text]
|
| 12.
|
Tsuda, M.,
Kitagawa, K.,
Imaizumi, K.,
Wanaka, A.,
Tohyama, M.,
and Takagi, T.
(1996)
Brain Res. Mol. Brain Res.
35,
314-318[Medline]
[Order article via Infotrieve]
|
| 13.
|
Tsuda, M.,
Imaizumi, K.,
Katayama, T.,
Kitagawa, K.,
Wanaka, A.,
Tohyama, M.,
and Takagi, T.
(1997)
J. Neurosci.
17,
6678-6684[Abstract/Free Full Text]
|
| 14.
|
Wang, X.,
Yue, T. L.,
Barone, F. C.,
White, R. F.,
Clark, R. K.,
Willette, R. N.,
Sulpizio, A. C.,
Aiyar, N. V.,
Ruffolo, R. R., Jr.,
and Feuerstein, G. Z.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11480-11484[Abstract/Free Full Text]
|
| 15.
|
Feuerstein, G. Z.,
and Wang, X.
(1997)
Can. J. Physiol. Pharmacol.
75,
731-734[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Clemens, J. A.,
Stephenson, D. T.,
Yin, T.,
Smalstig, E. B.,
Panetta, J. A.,
and Little, S. P.
(1998)
Stroke
29,
677-682[Abstract/Free Full Text]
|
| 17.
|
Pulsinelli, W. A.,
and Brierley, J. B.
(1979)
Stroke
10,
267-272[Abstract/Free Full Text]
|
| 18.
|
Gallo, V.,
Ciotti, M. T.,
Coletti, A.,
Aloisi, F.,
and Levi, G.
(1982)
Proc. Natl. Acad. Sci. U. S. A.
79,
7919-7923[Abstract/Free Full Text]
|
| 19.
|
Nicoletti, F.,
Wroblewski, J. T.,
Novelli, A.,
Alho, H.,
Guidotti, A.,
and Costa, E.
(1986)
J. Neurosci.
6,
1905-1911[Abstract]
|
| 20.
|
Sambrook, J., Fritsch, E. F., and Maniatis, T.
(eds)
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 21.
|
Genetics Computer Group.
(1997)
Wisconsin Package, Version 9.1
, Genetics Computer Group(GCG), Madison, WI
|
| 22.
|
Alwine, J. C.,
Kemp, D. J.,
Parker, B. A.,
Reiser, J.,
Renart, J.,
Stark, G. R.,
and Wahl, G. M.
(1979)
Methods Enzymol.
68,
220-242[Medline]
[Order article via Infotrieve]
|
| 23.
|
Weiner, A. M.,
Deininger, P. L.,
and Efstratiadis, A.
(1986)
Annu. Rev. Biochem.
55,
631-661[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Bladon, T. S.,
Fregeau, C. J.,
and McBurney, M. W.
(1990)
Mol. Cell. Biol.
10,
4058-4067[Abstract/Free Full Text]
|
| 25.
|
Basrai, M. A.,
Hieter, P.,
and Boeke, J. D.
(1997)
Genome Res.
7,
768-771[Free Full Text]
|
| 26.
|
Kramerov, D. A.,
Tillib, S. V.,
Lekakh, I. V.,
Ryskov, A. P.,
and Georgiev, G. P.
(1985)
Biochim. Biophys. Acta
824,
85-98[Medline]
[Order article via Infotrieve]
|
| 27.
|
Clemens, J. A.,
Saunders, R. D.,
Ho, P. P.,
Phebus, L. A.,
and Panetta, J. A.
(1993)
Stroke
24,
716-722[Abstract/Free Full Text]
|
| 28.
|
Nitatori, T.,
Sato, N.,
Waguri, S.,
Karasawa, Y.,
Araki, H.,
Shibanai, K.,
Kominami, E.,
and Uchiyama, Y.
(1995)
J. Neurosci.
15,
1001-1011[Abstract]
|
| 29.
|
Wang, S.,
Dibenedetto, A. J.,
and Pittman, R. N.
(1997)
Dev. Biol.
188,
322-336[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Gallo, V.,
Kingsbury, A.,
Balazs, R.,
and Jorgensen, O. S.
(1987)
J. Neurosci.
7,
2203-2213[Abstract]
|
| 31.
|
D'Mello, S. R.,
Galli, C.,
Ciotti, T.,
and Calissano, P.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
10989-10993[Abstract/Free Full Text]
|
| 32.
|
Du, Y.,
Bales, K. R.,
Dodel, R. C.,
Hamilton-Byrd, E.,
Horn, J. W.,
Czilli, D. L.,
Simmons, L. K.,
Ni, B.,
and Paul, S. M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11657-11662[Abstract/Free Full Text]
|
| 33.
|
Dodel, R. C.,
Du, Y.,
Bales, K. R.,
Ling, Z.,
Carvey, P. M.,
and Paul, S. M.
(1999)
Mol. Brain Res.
64,
141-148[Medline]
[Order article via Infotrieve]
|
| 34.
|
Choi, D. W.
(1988)
Neuron
1,
623-634[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Jellinger, K.,
Linert, L.,
Kienzl, E.,
Herlinger, E.,
and Youdim, M. B.
(1995)
J. Neural Transm.
46 (suppl.),
297-314
|
| 36.
|
Miller, T. M.,
Moulder, K. L.,
Knudson, C. M.,
Creedon, D. J.,
Deshmukh, M.,
Korsmeyer, S. J.,
and Johnson, E. M., Jr.
(1997)
J. Cell Biol.
139,
205-217[Abstract/Free Full Text]
|
| 37.
|
Rogers, J. H.
(1985)
Int. Rev. Cytol.
93,
187-279[Medline]
[Order article via Infotrieve]
|
| 38.
|
Krayev, A. S.,
Markusheva, T. V.,
Kramerov, D. A.,
Ryskov, A. P.,
Skryabin, K. G.,
Bayev, A. A.,
and Georgiev, G. P.
(1982)
Nucleic Acids Res.
10,
7461-7475[Abstract/Free Full Text]
|
| 39.
|
Bennett, K. L.,
Hill, R. E.,
Pietras, D. F.,
Woodworth-Gutai, M.,
Kane-Haas, C.,
Houston, J. M.,
Heath, J. K.,
and Hastie, N. D.
(1984)
Mol. Cell. Biol.
4,
1561-1571[Abstract/Free Full Text]
|
| 40.
|
Bachvarova, R.
(1988)
Dev. Biol.
130,
513-523[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Clemens, M. J.
(1987)
Cell
49,
157-158[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Krajewski, S.,
Mai, J. K.,
Krajewska, M.,
Sikorska, M.,
Mossakowski, M. J.,
and Reed, J. C.
(1995)
J. Neurosci.
15,
6364-6376[Abstract/Free Full Text]
|
| 43.
|
Chen, J.,
Zhu, R. L.,
Nakayama, M.,
Kawaguchi, K.,
Jin, K.,
Stetler, R. A.,
Simon, R. P.,
and Graham, S. H.
(1996)
J. Neurochem.
67,
64-71[Medline]
[Order article via Infotrieve]
|
| 44.
|
Chen, J.,
Graham, S. H.,
Nakayama, M.,
Zhu, R. L.,
Jin, K.,
Stetler, R. A.,
and Simon, R. P.
(1997)
J. Cereb. Blood Flow Metab.
17,
2-10[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Clemens, J. A.,
Stephenson, D. T.,
Dixon, E. P.,
Smalstig, E. B.,
Mincy, R. E.,
Rash, K. S.,
and Little, S. P.
(1997)
Brain Res. Mol. Brain Res.
48,
187-196[Medline]
[Order article via Infotrieve]
|
| 46.
|
Lin, K. I.,
Lee, S. H.,
Narayanan, R.,
Baraban, J. M.,
Hardwick, J. M.,
and Ratan, R. R.
(1995)
J. Cell Biol.
131,
1149-1161[Abstract/Free Full Text]
|
| 47.
|
Van Antwerp, D. J.,
Martin, S. J.,
Kafri, T.,
Green, D. R.,
and Verma, I. M.
(1996)
Science
274,
787-789[Abstract/Free Full Text]
|
| 48.
|
Fornace, A. J., Jr.,
Alamo, I., Jr.,
Hollander, M. C.,
and Lamoreaux, E.
(1989)
Exp. Cell Res.
182,
61-74[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Uberti, D.,
Belloni, M.,
Grilli, M.,
Spano, P.,
and Memo, M.
(1998)
Eur. J. Neurosci.
10,
246-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Blum, D.,
Wu, Y.,
Nissou, M. F.,
Arnaud, S.,
Alim Louis, B.,
and Verna, J. M.
(1997)
Brain Res.
751,
139-142[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Glinka, Y.,
Gassen, M.,
and Youdim, M. B.
(1997)
J. Neural Transm.
50 (suppl.),
55-66
|
| 52.
|
Ankarcrona, M.,
Dypbukt, J. M.,
Bonfoco, E.,
Zhivotovsky, B.,
Orrenius, S.,
Lipton, S. A.,
and Nicotera, P.
(1995)
Neuron
15,
961-973[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Enokido, Y.,
Araki, T.,
Tanaka, K.,
Aizawa, S.,
and Hatanaka, H.
(1996)
Eur. J. Neurosci.
8,
1812-1821[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Paterson, I. A.,
Zhang, D.,
Warrington, R. C.,
and Boulton, A. A.
(1998)
J. Neurochem.
70,
515-523[Medline]
[Order article via Infotrieve]
|
| 55.
|
Vasseur, M.,
Condamine, H.,
and Duprey, P.
(1985)
EMBO J.
4,
1749-1753[Medline]
[Order article via Infotrieve]
|
| 56.
|
Lania, L.,
Pannuti, A.,
La Mantia, G.,
and Basilico, C.
(1987)
FEBS Lett.
219,
400-404[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Ryskov, A. P.,
Ivanov, P. L.,
Tokarskaya, O. N.,
Kramerov, D. A.,
Grigoryan, M. S.,
and Georgiev, G. P.
(1985)
FEBS Lett.
182,
73-76[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Fornace, A. J., Jr.,
and Mitchell, J. B.
(1986)
Nucleic Acids Res.
14,
5793-5811[Abstract/Free Full Text]
|
| 59.
|
Liu, W. M.,
Chu, W. M.,
Choudary, P. V.,
and Schmid, C. W.
(1995)
Nucleic Acids Res.
23,
1758-1765[Abstract/Free Full Text]
|
| 60.
|
Edwards, D. R.,
Parfett, C. L.,
and Denhardt, D. T.
(1985)
Mol. Cell. Biol.
5,
3280-3288[Abstract/Free Full Text]
|
| 61.
|
Fuse, T.,
Yoon, K. W.,
Kato, T.,
and Yamada, K.
(1998)
Neurosurgery
42,
843-849[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Kurita, T.,
and Namiki, H.
(1994)
J. Cell. Physiol.
161,
63-70[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Sabbatini, P.,
Lin, J.,
Levine, A. J.,
and White, E.
(1995)
Genes Dev.
9,
2184-2192[Abstract/Free Full Text]
|
| 64.
|
Chen, S. L.,
Tsao, Y. P.,
Chen, Y. L.,
Huang, S. J.,
Chang, J. L.,
and Wu, S. F.
(1998)
Virology
244,
521-529[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Kim, H.,
Lee, H.,
and Yun, Y.
(1998)
J. Biol. Chem.
273,
381-385[Abstract/Free Full Text]
|
| 66.
|
Yamada, T.,
Yamaoka, S.,
Goto, T.,
Nakai, M.,
Tsujimoto, Y.,
and Hatanaka, M.
(1994)
J. Virol.
68,
3374-3379[Abstract/Free Full Text]
|
| 67.
|
Panning, B.,
and Smiley, J. R.
(1993)
Mol. Cell. Biol.
13,
3231-3244[Abstract/Free Full Text]
|
| 68.
|
Singh, K.,
Carey, M.,
Saragosti, S.,
and Botchan, M.
(1985)
Nature
314,
553-556[CrossRef][Medline]
[Order article via Infotrieve]
|
| 69.
|
Wang, H. D.,
Yuh, C. H.,
Dang, C. V.,
and Johnson, D. L.
(1995)
Mol. Cell. Biol.
15,
6720-6728[Abstract]
|
| 70.
|
Gottesfeld, J. M.,
Johnson, D. L.,
and Nyborg, J. K.
(1996)
Mol. Cell. Biol.
16,
1777-1785[Abstract]
|
| 71.
|
Carey, M. F.,
and Singh, K.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
7059-7063[Abstract/Free Full Text]
|
| 72.
|
Loeken, M.,
Bikel, I.,
Livingston, D. M.,
and Brady, J.
(1988)
Cell
55,
1171-1177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 73.
|
White, R. J.,
Stott, D.,
and Rigby, P. W.
(1990)
EMBO J.
9,
3713-3721[Medline]
[Order article via Infotrieve]
|
|